Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.

Ellen GinzlerLuiz Sergio Guedes BarbosaDavid D'CruzRichard A FurieKathleen Maksimowicz-McKinnonJames OatesMittermayer Barreto SantiagoAmit SaxenaSaira Z SheikhDamon L BassSusan W BurrissJennifer A GilbrideJames G GroarkMichelle MillerAmy PierceDavid A RothBeulah Ji

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

The primary end point of this study was not achieved, but improvement with belimumab versus placebo was observed, suggesting that belimumab remains a suitable treatment option for SLE management in patients of Black African ancestry.

Keyphrases

systemic lupus erythematosus
phase iii
end stage renal disease
disease activity
open label
newly diagnosed
ejection fraction
double blind
placebo controlled
peritoneal dialysis
prognostic factors
randomized controlled trial
phase ii
study protocol
smoking cessation